The Clinical Trials Unit

The Clinical Trials Unit offers children, adolescents, and adults diagnosed with a wide range of psychiatric disorders an opportunity to participate in innovative research and clinical trials.

Our team of experienced psychiatrists and clinicians promotes excellence in clinical care through cutting edge research on the latest medications and novel therapeutic options in hopes of improving patient outcomes and quality of life.


Staff | Overview | Participate in a Clinical Trial | Active Clinical Trials | Upcoming


Current Staff


Overview

Psychiatric clinical trials are highly regulated research studies using human volunteers to test the safety and efficacy of novel psychiatric drugs and treatments. Clinical trials are essential for developing new methods to prevent, diagnose, and treat psychiatric disorders. By participating in a clinical trial, patients can take an active role in managing their symptoms, gain access to novel research treatments before they are widely available, and help others by advancing our scientific understanding of the causes and contributors of psychiatric conditions.

CLINICAL TRIALS UNIT

The Clinical Trials Unit is located on the Hartford Hospital / Institute of Living campus in Hartford, CT. The service, directed by Drs. Mirjana Domakonda and Andrew Winokur, conducts controlled, clinical testing in human subjects of investigational psychiatric drugs, therapeutic modalities, or combined treatments that are currently in development but not yet approved for use in routine clinical care. Investigational drugs and/or treatments can only be administered to eligible individuals who are enrolled in a formal research study.

All research and clinical studies at the Clinical Trials Unit are conducted under investigator-initiated or industry-sponsored protocols with financial support from pharmaceutical companies, government agencies, and/or non-profit entities. The Hartford Healthcare Institutional Review Board, in conjunction with study sponsors and regulatory authorities, reviews, approves, and oversees all research and clinical trials at the Clinical Trials Unit.

Below you can find more information about currently running research and clinical trials and participant eligibility criteria. If you or a loved one are interested in participating in a research or clinical trial, please contact Ania Poltorak at 860-545-7265.


Participate in a Clinical Trial

COVID-19 Update: In an effort to protect the health and safety of our staff and study participants, the Clinical Trials Unit conducts screening prior to entering the building and requires that all participants and visitors wear a facial mask during their visit.

Our current and upcoming studies are listed below. For more information or to see if you or your loved one are eligible to participate in an ongoing or upcoming study, please email us at clinical.trials@hhchealth.org or call us 860-545-7476. We look forward to hearing from you.


Active Clinical Trials

Now Recruiting

MAJOR DEPRESSIVE DISORDER

ESKETINSUI2002 (Janssen) CURRENTLY RECRUITING PARTICIPANTS
Clinical trial to examine the efficacy and safety of an investigational medication - esketamine (given as a nasal spray) - in adolescents hospitalized with depression and suicidal ideation.

Qualified participants include:

  • Adolescents aged 12 to 17 years old
  • Have a diagnosis of major depressive disorder and are currently experiencing suicidal ideation
  • Currently prescribed or willing to switch to a study-approved antidepressant

Those that qualify will: 

  • Receive study-related care with a board-certified child and adolescent psychiatrist and other clinical staff at no cost
  • Receive reimbursement for study-related travel costs

For more information, contact clinical.trials@hhchealth.org or call us 860.545.7476

Now Recruiting

MAJOR DEPRESSIVE DISORDER

1402-0011 (Boehringer-Ingelheim) CURRENTLY RECRUITING PARTICIPANTS

Clinical trial to examine the efficacy and safety of an investigational medication compound compared to placebo in patients with Major Depressive Disorder.

Qualified participants include:

  • Adults aged 18 to 65 years old
  • Have a diagnosis of major depressive disorder
  • Currently prescribed a study-approved antidepressant (for at least ≥ 8 weeks)

Those that qualify will:

  • Receive study-related care with a board-certified psychiatrist and other clinical staff at no cost
  • Receive reimbursement for study participant and costs

For more information, contact clinical.trials@hhchealth.org or call us 860.545.7476

Now Recruiting

MAJOR DEPRESSIVE DISORDER WITH ANXIOUS DISTRESS

61393215MDD2001 (Janssen)
A randomized, double blind, multicenter, placebo controlled study to evaluate safety and efficacy and tolerability of JNJ-61393215 administered as an adjunctive treatment in adults with Major Depressive Disorder with Anxious Distress.

Qualified participants include:

  • Adults aged 18 to 64 years old
  • Have a diagnosis of major depressive disorder
  • Experience anxiety
  • Currently prescribed a study-approved antidepressant (for at least ≥ 6 weeks)

Those that qualify will:

  • Receive study-related care with a board-certified psychiatrist and other clinical staff at no cost
  • Receive reimbursement for study participation and costs

For more information, contact clinical.trials@hhchealth.org or call us 860.545.7476

Now Recruiting

POST-TRAUMATIC STRESS DISORDER (PTSD)

331-201-00071 (Otsuka) CURRENTLY RECRUITING PARTICIPANTS
Clinical trial to examine the efficacy and safety of brexpriprazole combined with sertraline as treatment for adults with posttraumatic stress disorder.

Qualified participants include:

  • Adults aged 18 to 65 years old
  • Have been diagnosed with posttraumatic stress disorder
  • Onset of symptoms for a minimum of 6 months prior to screening

Those that qualify will:

  • Receive study drug and study-related care with a board-certified psychiatrist and other clinical staff at no cost.
  • Receive reimbursement for study participation and costs.

For more information, contact clinical.trials@hhchealth.org or call us 860.545.7476

Back to Top


Upcoming Clinical Trials

Coming Soon

OBSESSIVE COMPULSIVE DISORDER

BHV4157-303 (Biohaven Pharmaceuticals, Inc)
New upcoming multicenter, randomized, double-blind, double dummy, placebo controlled study investigating the efficacy of troriluzole as an adjunctive therapy when added to standard of care to evaluate safety and tolerability of the investigational medication in obsessive compulsive disorder.

Stay tuned for more details!

Coming Soon

TREATMENT RESISTANT DEPRESSION

54135419TRD4005 (Janssen)
A randomized, double blind, multicenter, placebo controlled study to evaluate safety and efficacy and tolerability of esketamine nasal spray administered as a monotherapy for adults with treatment resistant depression.

Stay tuned for more details!

Coming Soon

MAJOR DEPRESSIVE DISORDER WITH SLEEP DISTURBANCE

42847922MDD3005 (Janssen)
A new upcoming multicenter, double-blind, randomized, parallel-group study looking to enroll adult and elderly participants to investigate the efficacy and safety of investigational medication compared with placebo in patients with major depressive disorder with insomnia symptoms who have responded inadequately to antidepressant therapy.

Stay tuned for more details!

Back to Top


Contact the Clinical Trials Unit


Join our Research Registry

If you are interested in participating in research at the Clinical Trials Unit follow the link below to sign up for our research registry. This will allow us to contact you for current and future research opportunities at the CTU. If you have any questions, email clinical.trials@hhchealth.org or call 860.545.7476.

Click here to join


Contact the Clinical Trials Unit


Join our Research Registry

If you are interested in participating in research at the Clinical Trials Unit follow the link below to sign up for our research registry. This will allow us to contact you for current and future research opportunities at the CTU. If you have any questions, email clinical.trials@hhchealth.org or call 860.545.7476.

Click here to join